PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2126554
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2126554
Europe, U.S., and India Liquid Biopsy Market is estimated to be valued at USD 169.2 Mn in 2026 and is expected to reach USD 535.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 17.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 169.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 17.90% | 2033 Value Projection: | USD 535.2 Mn |
The Europe, U.S., and India liquid biopsy market is expected to grow at a fast pace due to the increasing global burden of cancer, increasing demand for less invasive diagnostic technologies, and increasing adoption of precision oncology. Liquid biopsy has become an important tool for early detection of cancer, comprehensive genomic profiling, therapy selection, and treatment monitoring, offering a faster and less invasive alternative to conventional tissue biopsy.
Additionally, the market is driven by the continuous advancements in next generation sequencing (NGS), biomarker discovery and companion diagnostics, along with positive regulatory approvals and increasing reimbursement support in developed countries. Rising investments in oncology research, increasing clinical adoption in hospitals and diagnostic laboratories, and rapid expansion of molecular diagnostics infrastructure in India are expected to further propel the market growth.
The Europe, U.S., and India liquid biopsy market is primarily driven by the increasing prevalence of cancer, rising need of early and minimally invasive cancer diagnostics and growing adoption of precision medicine. Development in next-generation sequencing (NGS), companion diagnostics and biomarker analysis, along with favorable regulatory approvals and increasing clinical applications in oncology, are boosting the adoption of liquid biopsy technologies across the region.
However, a number of constraints are present in the market, such as high cost of liquid biopsy tests, limited reimbursement in certain clinical scenarios, and the need for extensive clinical validation and standardized testing protocols. Nevertheless, rising adoption of multi-cancer early detection (MCED) tests, expanding applications in minimal residual disease (MRD) monitoring and therapy response assessment, and increasing investments in molecular diagnostics infrastructure are expected to create significant growth opportunities over the forecast period.